RARE ULTRAGENYX PHARMACEUTICAL INC Product Launches 8-K Filing 2024 - FDA Designation Ultragenyx Pharmaceutical Inc. received Breakthrough Therapy Designation from the FDA for setrusumab (UX143) to treat osteogenesis imperfecta, based on positive clinical trial results showing a significant decrease in fracture rates.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC